The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products.
Key takeaways are that:
EU and Member State authorities imposed multiple material antitrust...more
The UK Competition and Markets Authority (CMA) has taken the unusual step of issuing a prioritisation statement on cooperation between competitors to make combination therapies available to the NHS.
The CMA worked closely...more
The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active pharmaceutical ingredient (API)...more
10/23/2023
/ Cartels ,
Cephalon ,
Competition ,
Corporate Counsel ,
EU ,
European Commission ,
Generic Drugs ,
Life Sciences ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Teva Pharmaceuticals
Public input -
As we wrote a couple of months ago, antitrust authorities of the US, Canada, UK, and EU formed, in March, an international working group: the Multilateral Pharmaceutical Merger Task Force (the Task Force)....more
Working group’s goal is “concrete and actionable” updates to pharmaceutical merger analysis....more
On 26 November 2020, the European Commission (Commission) issued a decision fining pharmaceutical companies Teva and Cephalon EUR60.5 million for infringing Article 101 TFEU by agreeing to delay the entry of a cheaper generic...more